Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials.
Esther J BeckAlexander D SherryMarcus A FlorezRamez KouzyJoseph Abi JaoudeTimothy A LinAvital M MillerAdina H PassyGabrielle S KupfermanRoshal R PatelFumiko L ChinoVictoria Serpas HigbieChristine M ParseghianMichael James OvermanBruce D MinskyCharles R ThomasChad TangPavlos MsaouelEthan Bernard LudmirPublished in: Cancer research communications (2024)
In this investigation, we characterized the utilization and publication rates of SEPs among late-phase oncology trials. Our results draw attention to the proliferation of SEPs in recent years. Although overall publication rates were high, underpublication was detected among endpoints that may increase patient burden (such as translational correlatives and patient-reported outcomes).